All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

tyrosine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2786	60-18-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tyrosine L-Tyrosine (S)-Tyrosine	A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin. Molecular weight: 181.19 Formula: C9H11NO3 CLOGP: -2.22 LIPINSKI: 0 HAC: 4 HDO: 3 TPSA: 83.55 ALOGS: -1.37 ROTB: 3 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
None	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Foetal growth restriction	63.26	26.19	15	680	7538	63480789
Infantile apnoea	44.55	26.19	8	687	1025	63487302
Selective eating disorder	38.99	26.19	8	687	2064	63486263
Cerebral haemorrhage	31.33	26.19	12	683	30717	63457610
Device related sepsis	28.44	26.19	7	688	4087	63484240

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
CHEBI has role	CHEBI:27027	trace elements
CHEBI has role	CHEBI:50733	Dietary Supplement
CHEBI has role	CHEBI:64416	arogenate dehydrogenase inhibitors
CHEBI has role	CHEBI:78675	fundamental metabolites
CHEBI has role	CHEBI:83056	Daphnia magna metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.27	acidic
pKa2	10.4	acidic
pKa3	9.25	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Large neutral amino acids transporter small subunit 1	Transporter	Q01650	LAT1_HUMAN		IC50	4.17		CHEMBL

External reference:

ID	Source
4018678	VUID
N0000146989	NUI
D00022	KEGG_DRUG
4018678	VANDF
C0041485	UMLSCUI
CHEBI:18186	CHEBI
TYR	PDB_CHEM_ID
CHEMBL925	ChEMBL_ID
DB00135	DRUGBANK_ID
D014443	MESH_DESCRIPTOR_UI
6057	PUBCHEM_CID
6174	INN_ID
4791	IUPHAR_LIGAND_ID
42HK56048U	UNII
10962	RXNORM
15487	MMSL
187423	MMSL
40047	MMSL
NOCODE	MMSL
d07831	MMSL
003449	NDDF
27378009	SNOMEDCT_US
418246001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-1933	SOLUTION	0.04 g	INTRAVENOUS	NDA	23 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-1933	SOLUTION	0.04 g	INTRAVENOUS	NDA	23 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-1933	SOLUTION	0.04 g	INTRAVENOUS	NDA	23 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-3200	SOLUTION	39 mg	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-3205	SOLUTION	39 mg	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-4500	SOLUTION	39 mg	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-4500	SOLUTION	39 mg	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-4500	SOLUTION	39 mg	INTRAVENOUS	ANDA	20 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-9341	SOLUTION	0.04 g	INTRAVENOUS	NDA	23 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-9361	SOLUTION	0.04 g	INTRAVENOUS	NDA	23 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0180	INJECTION	32 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0180	INJECTION	32 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0184	INJECTION, EMULSION	32 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0184	INJECTION, EMULSION	32 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0188	INJECTION	32 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0188	INJECTION	32 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0194	INJECTION	32 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0194	INJECTION	32 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0198	INJECTION	24 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0198	INJECTION	24 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	32 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	32 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	32 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0206	INJECTION	32 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0206	INJECTION	32 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0206	INJECTION	32 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0210	INJECTION	32 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0210	INJECTION	32 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0210	INJECTION	32 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0214	INJECTION	32 mg	INTRAVENOUS	NDA	20 sections